Bio Sequence

Biological Glossary | What is Linker?

8 November 2023
2 min read

In biology, linkers refer to short amino acid sequences found in nature that separate multiple domains in a single protein. They function to prohibit unwanted interactions between discrete domains. Some linkers, like Gly-rich linkers, are more flexible and do not interfere with each domain's function. Linkers can also be artificial, created through recombinant DNA technology to fuse two interacting partners. Given their variability, linkers have many utilities in the biological field, such as improving protein quality, stabilizing protein-protein complexes, and facilitating the production of protein dimers.

Alternatively, linkers in molecular biology can refer to short, synthetic DNA or RNA sequences. These are designed to show specific properties, such as containing restriction enzyme recognition sites, or functioning as ligatable ends. These are mainly used to modify or manipulate DNA or RNA molecules during various molecular biology techniques. 

Free registration is available for the Bio biological sequence database: https://bio-patsnap-com.libproxy1.nus.edu.sg. Act now to expedite your sequence search tasks.

图片包含 图示

描述已自动生成

The phase 2 clinical trial of Otsuka/Visterra's anti-APRIL monoclonal antibody, sibeprenlimab, for the treatment of IgA nephropathy is published in the NEJM
Latest Hotspot
3 min read
The phase 2 clinical trial of Otsuka/Visterra's anti-APRIL monoclonal antibody, sibeprenlimab, for the treatment of IgA nephropathy is published in the NEJM
8 November 2023
Otsuka Pharmaceutical and Visterra recently reported that the full Phase II trial results for sibeprenlimab (VIS649), a treatment for IgA nephropathy, have been published in the NEJM.
Read →
Biological Glossary | What is Intron?
Bio Sequence
2 min read
Biological Glossary | What is Intron?
8 November 2023
An intron, derived from the term "intragenic region", is a nucleotide sequence within a gene that does not directly code for proteins and does not remain in the final mature mRNA molecule following the gene's transcription.
Read →
The first participant has been administered HG004 in an international phase 1/2 study against hereditary blindness, as disclosed by Huidagene Therapeutics
Latest Hotspot
3 min read
The first participant has been administered HG004 in an international phase 1/2 study against hereditary blindness, as disclosed by Huidagene Therapeutics
8 November 2023
HuidaGene Therapeutics, a global oncology-focused biotech company, has announced its first treatment in its multinational HG004 gene therapy study (STAR study). This phase 1/2a investigation uses CRISPR-influenced programmable genomic drugs to potentially treat inherited retinal dystrophies caused by RPE65 gene mutations.
Read →
Patent Analysis of Jiangsu Hengrui's PARP1 Inhibitor HRS-1167
Hot Spotlight
6 min read
Patent Analysis of Jiangsu Hengrui's PARP1 Inhibitor HRS-1167
8 November 2023
In late October, Hengrui and Merck agreed on a €1.4 billion transaction, with a first payment of €160 million. The deal mainly involves Hengrui's self-developed PARP1 inhibitor HRS-1167 and Claudin-18.2 ADC SHR-A1904.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.